Fondazione Italiana Linfomi - Ets

This study is testing whether a daily oral medication called pirtobrutinib can help control mantle cell lymphoma in older adults who are too frail for standard chemotherapy. It will enroll 56 previously untreated patients aged 70+ who are considered unfit or frail. Participants w…

This study tests an experimental drug called glofitamab for people with mantle cell lymphoma whose cancer didn't respond well enough or came back after CAR-T cell therapy. About 41 participants will receive the drug to see if it can shrink their cancer and how safe it is. The goa…

This study is testing whether adding a geriatric support plan to standard cancer treatment improves life quality for older, frail patients with aggressive lymphoma. It will compare two groups: one receiving standard cancer care and another receiving cancer care plus extra support…

This study aims to see if patients with early-stage Hodgkin lymphoma who respond well to chemotherapy can safely receive a lower dose of radiation therapy. Researchers will compare a reduced radiation dose (20 Gy) to the standard dose (30 Gy) in 518 patients to see if the lower d…

This study aims to understand how well a recently approved drug combination works for a rare blood cancer in real-world patients, not just in a controlled trial. Researchers will look back at the health records of 100 patients already treated with this drug and analyze their stor…

This study aims to understand how CAR-T cell therapy affects memory, thinking skills, and quality of life in adults with certain aggressive lymphomas. Researchers will follow 100 patients in Italy for two years, starting assessments before treatment and checking in at 6, 12, and …